An analysis of tivozanib versus sorafenib in patients with advanced renal cell carcinoma (RCC) included in the phase 3 TIVO-3 study revealed that, as a third- or fourth-line treatment, tivozanib significantly increased quality-adjusted time without symptoms of disease and toxicity (Q-TWiST) compared with sorafenib, primarily through an increase in TWiST.1
Overall, these results, presented at the American Society of Clinical Oncology (ASCO) 2021 Genitourinary Cancers Symposium, suggestQ-TWiST may be considered an alternative patient-centered measure of benefit of tivozanib in these settings.
In an interview with CancerNetwork®, Michael Szarek, PhD, of the SUNY Downstate Medical Center, discussed the rationale behind conducting this analysis.
The TIVO-3 study was [for the] third- or fourth-line treatment of patients with metastatic renal cell carcinoma. The primary results…